ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AstraZeneca and Beijing Biotech side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AstraZenecaBeijing Biotech
studies on the registry4,19732
open to participants now29832
phase 3 studies under way2000
reach primary completion within a year16831
programswith a study of their own in two years119+5 named only40

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAstraZenecaBeijing Biotech
Phase 1

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Beijing Biotech: 1 of its 40 programs at phase 1

  1. ETB-DualNK-01phase 1
3%
Phase 2

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

Beijing Biotech: 39 of its 40 programs at phase 2

  1. Cyclophosphamidephase 2
  2. fludarabinephase 2
  3. Dual-target CAR-NK cellsphase 2
  4. ebnk-1822h2 dual-target cldn18.2phase 2
  5. Lymphodepleting chemotherapyphase 2

and 34 more — sign in to see them all

98%
Phase 3

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%
00%
Approved, new studies

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Beijing Biotech40 readouts · 0 phase 3···

Beijing Biotech, Feb ’27: 11 programs whose next study reaches primary completion

  1. Dual-target CAR-NK cellsphase 2 · Feb 14 · NCT07467863
  2. Dual-target CAR-NK cells (EB-DT-CAR-NK)phase 2 · Feb 14 · NCT07486089
  3. EB-DART-NK01phase 2 · Feb 14 · NCT07744256
  4. EB-DART-NK01 (DLL3/CD56 CAR-NK cells)phase 2 · Feb 14 · NCT07480213
  5. EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)phase 2 · Feb 14 · NCT07480928

and 6 more — sign in to see them all

Beijing Biotech, Mar ’27: 21 programs whose next study reaches primary completion

  1. Autologous Anti-CD19 CAR-expressing T Lymphocytesphase 2 · Mar 14 · NCT07523542
  2. Autologous BCMA/CD19 dual-target CAR-T modulephase 2 · Mar 14 · NCT07523555
  3. Autologous BCMA/CD38 dual-target CAR-T modulephase 2 · Mar 14 · NCT07523555
  4. Autologous BCMA/GPRC5D dual-target CAR-Tphase 2 · Mar 14 · NCT07523555
  5. Autologous CD19/CD20 dual-target CAR-T modulephase 2 · Mar 14 · NCT07523555

and 16 more — sign in to see them all

Beijing Biotech, Apr ’27: 3 programs whose next study reaches primary completion

  1. Autologous dual-target CAR-T cells selected from the predefined target library.phase 2 · Apr 14 · NCT07523529
  2. eb-701phase 2 · Apr 14 · NCT07551349
  3. EB-701/CA9-NKphase 2 · Apr 14 · NCT07551349
·

Beijing Biotech, Jun ’27: 5 programs whose next study reaches primary completion

  1. AP 1903 reagentphase 2 · Jun 14 · NCT07598955
  2. EB-CAR30-NKphase 2 · Jun 14 · NCT07598955
  3. EB-CAR5-NKphase 2 · Jun 14 · NCT07598955
  4. EB-CARMSLN-NKphase 2 · Jun 14 · NCT07598955
  5. EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cellsphase 2 · Jun 14 · NCT07627698
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Beijing Biotech

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 22 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionAstraZenecaBeijing Biotech
Carcinoma, Non-Small-Cell Lungboth · compare here

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Beijing Biotech in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. Cyclophosphamidephase 2
  2. Dual-target CAR-NK cellsphase 2

Their studies: Beijing Biotech’s studies of Carcinoma, Non-Small-Cell Lung in search

Prostatic Neoplasmsboth · compare here

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

Beijing Biotech in Prostatic Neoplasms: 2 programs

  1. AP 1903 reagentphase 2
  2. ETB-DualNK-01phase 1

Their studies: Beijing Biotech’s studies of Prostatic Neoplasms in search

Breast Neoplasmsboth · compare here

AstraZeneca in Breast Neoplasms: 10 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

Beijing Biotech in Breast Neoplasms: 1 program

  1. Cyclophosphamidephase 2

Their studies: Beijing Biotech’s studies of Breast Neoplasms in search

Neoplasmsboth · compare here

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Beijing Biotech in Neoplasms: 4 programs

  1. Lymphodepleting chemotherapyphase 2
  2. Cytokine supportphase 2
  3. EB-PT-CAR-NK-Dphase 2
  4. EB-PT-CAR-NK-Sphase 2

Their studies: Beijing Biotech’s studies of Neoplasms in search

Burkitt Lymphomaboth · compare here
Stomach Neoplasmsboth · compare here

Beijing Biotech in Stomach Neoplasms: 1 program

  1. EB-DT-CAR-NKphase 2

Their studies: Beijing Biotech’s studies of Stomach Neoplasms in search

Leukemia, Lymphocytic, Chronic, B-Cellboth · compare here

AstraZeneca in Leukemia, Lymphocytic, Chronic, B-Cell: 5 programs

  1. surovatamigphase 3
  2. ceralasertibphase 3
  3. monalizumabphase 3
  4. pirtobrutinibphase 2
  5. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Beijing Biotech in Leukemia, Lymphocytic, Chronic, B-Cell: 2 programs

  1. Cyclophosphamidephase 2
  2. fludarabinephase 2

Their studies: Beijing Biotech’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Multiple Myelomaboth · compare here

Beijing Biotech in Multiple Myeloma: 2 programs

  1. Cyclophosphamidephase 2
  2. fludarabinephase 2

Their studies: Beijing Biotech’s studies of Multiple Myeloma in search

Neoplasm Metastasisboth · compare here

AstraZeneca in Neoplasm Metastasis: 3 programs

  1. saruparibphase 3
  2. camizestrantphase 3
  3. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Neoplasm Metastasis in search

Triple Negative Breast Neoplasmsboth · compare here

AstraZeneca in Triple Negative Breast Neoplasms: 4 programs

  1. datopotamab deruxtecanphase 3
  2. capivasertibphase 3
  3. ceralasertibphase 3
  4. Actinium-225phase 3

Their studies: AstraZeneca’s studies of Triple Negative Breast Neoplasms in search

Beijing Biotech in Triple Negative Breast Neoplasms: 2 programs

  1. Dual-target CAR-NK cellsphase 2
  2. Dual-target CAR-NK cells (EB-DT-CAR-NK)phase 2

Their studies: Beijing Biotech’s studies of Triple Negative Breast Neoplasms in search

Small Cell Lung Carcinomaboth · compare here

AstraZeneca in Small Cell Lung Carcinoma: 2 programs

  1. tremelimumabphase 3
  2. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Small Cell Lung Carcinoma in search

Carcinoma, Ovarian Epithelialboth · compare here

AstraZeneca in Carcinoma, Ovarian Epithelial: 1 program

  1. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Carcinoma, Ovarian Epithelial in search

Beijing Biotech in Carcinoma, Ovarian Epithelial: 3 programs

  1. Lymphodepleting chemotherapyphase 2
  2. Dual-target CAR-NK cell productphase 2
  3. EB-DUALNKphase 2

Their studies: Beijing Biotech’s studies of Carcinoma, Ovarian Epithelial in search

Show all 22

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: AstraZeneca 68 of 119 · Beijing Biotech 1 of 40 programs (30 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5).